Medications That Can Quietly Increase Cardiac Risk
When I first started working in clinical pharmacology, I reviewed a case file that stuck with me. An elderly woman in her late seventies was being treated for a resistant infection with levofloxacin. She was also on a low dose of methadone for chronic pain, plus sotalol for atrial fibrillation. Standard three-drug combo. She had no prior history of arrhythmia. She went into torsades de pointes at home and didn't make it to the hospital in time. The chart review was brutal but clear. Every single one of those drugs carries some QT risk on its own. Together, they crossed a threshold nobody flagged. I need to be straight about something most people don't understand going into this. Sudden cardiac death from medication isn't usually dramatic or unpredictable in retrospect. It is almost always the result of overlapping risks that compound rather than simply add up. A drug that is perfectly safe at therapeutic doses in isolation can become dangerous when combined with another, or when kidney function dips and serum concentrations climb without warning. The mechanism is usually QT prolongation leading to a fatal arrhythmia called torsades de pointes. Sometimes it is a different pathway entirely, like sodium channel blockade causing ventricular fibrillation. Understanding which mechanism is at play matters more than memorizing a list. Here are the ten categories and specific medications most consistently linked to increased risk, along with what actually happens in practice.
1. Methadone This one gets ignored constantly. Methadone has a long half-life that varies wildly between individuals, sometimes extending past a hundred hours. It blocks the hERG potassium channel directly, which prolongs the QT interval in a dose-dependent manner. The risk really kicks in above 100 milligrams per day, but serious events have been documented at much lower doses, especially when combined with other agents. The practical issue is that methadone accumulates. Patients often do not feel intoxicated or sedated as the dose climbs because tolerance develops to the opioid effects faster than to the cardiac effects. I once watched a patient's QTc creep from 440 to 520 over three weeks while his pain control seemed to be improving. Nobody caught it because nobody was checking the ECG after the first week. The workaround is baseline and periodic ECG monitoring, absolutely mandatory when methadone is part of any regimen. 2. Sotalol
Sotalol is a beta-blocker with class III antiarrhythmic properties, which means it prolongs repolarization and therefore the QT interval. It is one of the most predictable offenders. The cardiac risk here is not theoretical. Clinical trials showed a measurable increase in mortality in the CAST trial era for similar drugs, and sotalol carries a black box warning for proarrhythmia. The nuance most prescribers miss is that renal clearance dominates elimination. A patient who starts normal on sotalol but then develops dehydration from an unrelated illness can see their drug levels spike sharply. Dose adjustment based on creatinine clearance is not optional, and I would say it is rarely done rigorously enough in real-world practice. If you are using sotalol, you need a current creatinine clearance calculation, not just a casual glance at serum creatinine. 3. Haloperidol and other typical antipsychotics Haloperidol, especially at higher doses or through IV administration, carries a well-documented risk. The FDA issued a safety warning about this in 2007, and the data backs it up. The problem is that antipsychotics are often prescribed in settings where ECG monitoring is not standard practice. Acute psychiatric emergencies, emergency department agitation, nursing home patients with delirium. These are exactly the populations where risk factors like hypokalemia, hypomagnesemia, and structural heart disease are most common, and where they are least likely to be checked. The counter-intuitive part is that oral haloperidol at low doses like 0.5 to 2 milligrams carries far less risk than the IV route, but IV haloperidol remains widely used for rapid tranquilization. If you have to use it, check the QT interval first and correct electrolytes aggressively before and during administration. Droperidol carries an even heavier warning and is basically off-label for most uses now.
Get the Full Details
4. Fluoroquinolone antibiotics Ciprofloxacin, levofloxacin, moxifloxacin. These are extremely commonly prescribed, and the cardiac risk is dose- and drug-dependent. Moxifloxacin has the strongest signal. The mechanism involves blocking the slow component of the delayed rectifier potassium current. What makes this category particularly dangerous in practice is the sheer volume of prescriptions. A side effect that affects one in several thousand patients becomes a public health issue when millions of courses are written annually. The risk is dramatically amplified in older patients, those with known QT prolongation, or anyone on concurrent QT-prolonging drugs. I routinely flag fluoroquinolones in clinical pharmacy consultations when the prescriber has not reviewed the medication list for interactions. It saves problematic combinations from reaching the dispensary. 5. Macrolide antibiotics
Erthromycin and clarithromycin are the main culprits here. Azithromycin has a weaker signal but is not risk-free, particularly at higher doses or in vulnerable populations. Macrolides inhibit the CYP3A4 enzyme, which creates a double problem. They prolong the QT directly, and they also increase the serum levels of many other QT-prolonging drugs through metabolic interaction. A patient on sotalol who is prescribed clarithromycin is effectively getting an unintentional sotalol dose increase. This interaction is one of the most common and most dangerous medication errors I encounter. Always run a CYP3A4 interaction check before combining macrolides with any cardiac medication. 6. Tricyclic antidepressants Amitriptyline, nortriptyline, imipramine, and the rest. TCAs block cardiac sodium channels at higher concentrations, which can produce a QRS widening pattern that predisposes to ventricular arrhythmias. They also have anticholinergic and alpha-blocking effects that complicate the picture. The toxicity window between therapeutic and dangerous doses is narrower than many clinicians appreciate. Overdose with TCAs is a leading cause of fatal arrhythmia in poisoning cases, but even therapeutic dosing can be problematic in patients with underlying conduction disease. The classic teaching is to avoid TCAs in patients with known heart disease, but the reality is that many patients with cardiac conditions continue on TCAs prescribed years earlier without reassessment. Periodic ECG monitoring in elderly patients on TCAs is cheap and often reveals conduction abnormalities that were previously unnoticed.
7. Ondansetron and other 5-HT3 antagonists Ondansetron was long considered completely safe, and for most patients it is. But the QT-prolonging effect became apparent in post-marketing surveillance and meta-analyses. The risk is higher with IV administration and at doses above 16 milligrams per day. The FDA added a warning about this in 2011. The clinical pearl here is that the risk is real but small in absolute terms, and it is concentrated in specific subgroups. Patients with congenital long QT syndrome, electrolyte disturbances, or concurrent use of other QT-prolonging drugs are the ones who should be watched. For the average chemotherapy patient getting standard-dose ondansetron with normal electrolytes, the risk is negligible. Don't avoid ondansetron out of fear. Just be aware of the context. 8. Class IA and III antiarrhythmics
Quinidine, procainamide, disopyramide, and amiodarone. This is almost a joke in the sense that prescribing antiarrhythmic drugs to prevent arrhythmia while risking fatal arrhythmia is the central tension of this entire category. Amiodarone is the most commonly used of these and has the most complex safety profile. It causes thyroid dysfunction, pulmonary fibrosis, hepatotoxicity, corneal deposits, and skin discoloration, in addition to QT prolongation. The ironic part is that amiodarone actually has a lower risk of torsades than sotalol or dofetilide despite prolonging the QT more, because it also blocks beta receptors and calcium channels, which somewhat counteracts the repolarization effect. But that does not make it safe. The monitoring requirements are extensive and ongoing. Baseline and periodic chest X-rays, thyroid function tests, liver enzymes, and ophthalmologic exams. If you are managing a patient on amiodarone without this monitoring, you are not practicing good medicine. 9. Antihistamines Terfenadine and astemizole were pulled from the market for exactly this reason. They caused fatal arrhythmias when co-administered with CYP3A4 inhibitors like ketoconazole or erythromycin. The modern equivalents are less risky but not zero-risk. First-generation antihistamines like diphenhydramine have sodium channel blocking properties in overdose and can cause QT prolongation at high doses. Second-generation antihistamines are much safer, but desloratadine and levocetirizine have been associated with rare cases of QT prolongation. The practical concern here is usually polypharmacy in elderly patients who are taking over-the-counter medications alongside prescription drugs without realizing the cumulative effect. Someone might take a cold remedy containing diphenhydramine on top of their regular medications without thinking about it. Medication reconciliation should always include OTC products.
10. Antifungals and other CYP3A4 inhibitors Ketoconazole, itraconazole, voriconazole, and clarithromycin all inhibit CYP3A4. When they inhibit the metabolism of QT-prolonging drugs, they create secondary risk. This is the interaction category that causes the most preventable adverse events. A patient on a stable dose of dofetilide who gets prescribed ketoconazole for a fungal infection can see their dofetilide levels multiply several times over. The same applies to colchicine, statins, and many other drugs. The principle is simple but easily missed: any new prescription can change the pharmacokinetics of an existing one. When adding a known CYP3A4 inhibitor to a regimen that includes QT-prolonging drugs, check the interaction database and monitor appropriately. The honest assessment of this whole topic is that medication-related sudden cardiac death is largely preventable, but prevention requires vigilance that the current healthcare system does not consistently provide. Most of these events happen because someone added a new drug without reviewing the full medication list, or because monitoring was not performed at the right intervals. The single most effective intervention is a thorough medication review at every encounter, including OTC drugs and supplements, combined with periodic ECG monitoring in at-risk patients. Electrolyte management, particularly potassium and magnesium, is another underappreciated protective factor. Hypokalemia and hypomagnesemia lower the threshold for torsades dramatically, and they are common in hospitalized patients who are not being monitored closely enough.
If you or someone you know is taking any of these medications, do not stop them abruptly. Sudden discontinuation of drugs like sotalol or TCAs can itself be dangerous. Discuss any concerns with the prescribing clinician and request an assessment of your individual risk based on your full medical history, current medications, and relevant lab values.
